Previous 10 | Next 10 |
Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the mutant gene tied to diseases such as ALS and Huntington's. DNA-targeted therapies are po...
BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...
The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Sangamo Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Sangamo Therapeutics, Inc. (SGMO) Q3 2020 Earnings Conference Call November 4, 2020 17:00 ET Company Participants Aron Feingold - Head, Corporate Communications Sandy Macrae - Chief Executive Officer Sung Lee - Chief Financial Officer Mark McClung - Chief Business Officer Jason Fontenot - Int...
Image source: The Motley Fool. Sangamo Therapeutics Inc (NASDAQ: SGMO) Q3 2020 Earnings Call Nov 4, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Sangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call Transcript
Sangamo Therapeutics (SGMO): Q3 GAAP EPS of -$0.01 beats by $0.24.Revenue of $57.76M (+163.0% Y/Y) beats by $32.65M.Press Release For further details see: Sangamo Therapeutics EPS beats by $0.24, beats on revenue
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. “We are pleased with the clinical execution ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020. The press release will be followed by a conference call a...
Biogen has embraced Ionis antisense technology for neurology targets. A new Gene Therapy Accelerator Unit was formed last year and has facilitated the creation of new business units and collaborations in 2020. The stock has been in a holding pattern for six years. Once pipeline pr...
Palm Beach, FL – October 13, 2020 – The number of new cases of brain cancer across the world has been growing consistently for years and it is projected to continue on this upward path, which leads to recent reports projecting that the global treatment markets should also see ...
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
2024-05-15 13:30:05 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for SGMO on May 15, 2024 11:01AM ET. The previous analyst recommendation was Underperform. SGMO was trading at $0.5901 at issue of the analyst recommendation. The overall analyst consensus ...
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrie...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from...